GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (ASX:ATX) » Definitions » Selling, General, & Admin. Expense

Amplia Therapeutics (ASX:ATX) Selling, General, & Admin. Expense : A$2.69 Mil (TTM As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Amplia Therapeutics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Amplia Therapeutics's selling, general, & admin. expense for the six months ended in Sep. 2023 was A$1.26 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Sep. 2023 was A$2.69 Mil.


Amplia Therapeutics Selling, General, & Admin. Expense Historical Data

The historical data trend for Amplia Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Selling, General, & Admin. Expense Chart

Amplia Therapeutics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.06 1.35 1.70 2.41 2.69

Amplia Therapeutics Semi-Annual Data
Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 1.07 1.33 1.26 1.43

Competitive Comparison of Amplia Therapeutics's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Amplia Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amplia Therapeutics's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Selling, General, & Admin. Expense falls into.



Amplia Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$2.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amplia Therapeutics  (ASX:ATX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Amplia Therapeutics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Amplia Therapeutics (ASX:ATX) Business Description

Industry
Traded in Other Exchanges
Address
350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (ASX:ATX) Headlines

No Headlines